Top

Published in:

01-01-2012 | Brief Report

The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms

Authors: Victoria K. Shanmugam, James McCloskey, Beth Elston, Sandra J. Allison, Jennifer Eng-Wong

Published in: Breast Cancer Research and Treatment | Issue 2/2012

Abstract

Aromatase inhibitors (AIs) are widely prescribed for post-menopausal hormone receptor-positive breast cancer; however, musculoskeletal symptoms limit their tolerability. The purpose of this study was to determine whether joint pain in women receiving AIs is associated with inflammatory arthritis as measured by the disease activity score-28 (DAS-28), and to evaluate association with tenosynovitis on ultrasound. A total of 48 postmenopausal women with stage I–III breast cancer and hand pain were recruited from the Lombardi Comprehensive Cancer Center. Those receiving AIs were cases (n = 25), and those not receiving AIs were controls (n = 23). During a single study visit, subjects underwent blinded rheumatologic evaluation, DAS-28, health assessment questionnaires, autoantibodies, inflammatory markers, hand X-ray, and hand Duplex ultrasound. There were no significant differences between cases and controls in DAS-28, or inflammatory markers. A positive ANA (titer > 1:160) was found in ten patients, four of whom met criteria for autoimmune disease (two with rheumatoid arthritis and two with Sjogren’s syndrome, equally distributed among cases and controls). This highlights the importance of considering underlying autoimmune disease in subjects with musculoskeletal complaints. Morning stiffness was more prolonged in women receiving AIs, but this did not reach statistical significance (P = 0.07). Ultrasound evidence of flexor tenosynovitis was common in both groups. Although tenosynovitis was not correlated with AI use (P = 0.26), there was a trend toward an association between tenosynovitis and morning stiffness (P = 0.089). While aromatase inhibitor-induced musculoskeletal symptoms (AIMSS) were more common in subjects receiving AIs, they were not unique to AI users. There was no association between presence of AIMSS features and other chemotherapy or medication exposures. Although the majority of subjects had been using AIs for more than 6 months, this study did not find evidence for inflammatory arthritis in women with hand pain receiving AIs. Further studies are needed to develop a case definition of AIMSS, and to confirm whether these symptoms are attributable to AI use.

Baum M, Cuzick J, Forbes J, Houghton J, Klijn J, Sahmoud T (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324):2131–2139PubMedCrossRef

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes J, Hoctin-Boes G, Houghton J, Locker G, Tobias J (2005) Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365(9453):60–62PubMedCrossRef

Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) a randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081–1092. doi:10.1056/NEJMoa040331 PubMedCrossRef

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19):1793–1802. doi:10.1056/NEJMoa032312 PubMedCrossRef

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23(3):619–629. doi:10.1200/jco.2005.09.121 PubMedCrossRef

Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol 28(23):3784–3796. doi:10.1200/jco.2009.26.3756 PubMedCrossRef

Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. The Breast 16(3):223–234PubMedCrossRef

Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3):275–282PubMedCrossRef

Burstein HJ, Winer EP (2007) Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol 25(25):3797–3799. doi:10.1200/jco.2007.11.9529 PubMedCrossRef

10.

Morales L, Pans S, Paridaens R, Westhovens R, Timmerman D, Verhaeghe J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Van Limbergen E, Weltens C, Van den Bogaert W, De Smet L, Vergote I, Christiaens M, Neven P (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104(1):87–91PubMedCrossRef

11.

Henry N, Jacobson J, Banerjee M, Hayden J, Smerage J, Van Poznak C, Storniolo A, Stearns V, Hayes D (2010) A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography. Cancer 116(18):4360–4367. doi:10.1002/cncr.25385 PubMedCrossRef

12.

Henry NL, Pchejetski D, A’Hern R, Nguyen AT, Charles P, Waxman J, Li L, Storniolo AM, Hayes DF, Flockhart DA, Stearns V, Stebbing J (2010) Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer 103(3):291–296. doi:http://www.nature.com/bjc/journal/v103/n3/suppinfo/6605768s1.html

13.

Lintermans A, Van Calster B, Van Hoydonck M, Pans S, Verhaeghe J, Westhovens R, Henry NL, Wildiers H, Paridaens R, Dieudonné AS, Leunen K, Morales L, Verschueren K, Timmerman D, De Smet L, Vergote I, Christiaens MR, Neven P (2011) Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol 22(8):1763–1769. doi:10.1093/annonc/mdq699 PubMedCrossRef

14.

Winters L, Habin K, Flanagan J, Cashavelly B (2010) I feel like i am 100 years old! Managing arthralgias from aromatase inhibitors. Clin J Oncol Nurs 14(3):379–382PubMedCrossRef

15.

Dizdar O, Ozcakar L, Malas FU, Harputluoglu H, Bulut N, Aksoy S, Ozisik Y, Altundag K (2009) Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol 27(30):4955–4960. doi:10.1200/jco.2008.20.5435 PubMedCrossRef

16.

Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, DeMichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16):3631–3639. doi:10.1002/cncr.24419 PubMedCrossRef

17.

Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25):3877–3883. doi:10.1200/jco.2007.10.7573 PubMedCrossRef

18.

Cuzick J, Sestak I, Cella D, Fallowfield L (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12):1143–1148. doi:10.1016/s1470-2045(08)70259-6 PubMedCrossRef

19.

Henry N, Giles J, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes D, Storniolo AM, Clauw D (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2):365–372. doi:10.1007/s10549-007-9774-6 PubMedCrossRef

20.

Laroche M, Borg S, Lassoued S, De Lafontan B, Roché H (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjögren’s syndrome. J Rheumatol 34(11):2259–2263PubMed

21.

Moxley G (2010) Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clin Breast Cancer 10(2):144–147PubMedCrossRef

22.

Morales L, Pans S, Verschueren K, Van Calster B, Paridaens R, Westhovens R, Timmerman D, De Smet L, Vergote I, Christiaens M-R, Neven P (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19):3147–3152. doi:10.1200/jco.2007.15.4005 PubMedCrossRef

23.

Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52(9):2594–2598PubMedCrossRef

24.

Kushner I (1991) C-reactive protein in rheumatology. Arthritis Rheum 34(8):1065–1068PubMedCrossRef

25.

Prevoo M, Van Riel P, Van ‘T Hof M, Van Rijswijk M, Van Leeuwen M, Kuper H, Van De Putte L (1993) Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis. Br J Rheumatol 32(7):589–594PubMedCrossRef

26.

Pincus T (2008) Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid. Arthritis Bull NYU Hosp Joint Dis 66(3):216–223

27.

Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, Cooke T, Daniel W, Gray R (1990) The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33(11):1601–1610PubMedCrossRef

28.

Wolfe F, Smythe H, Yunus M, Bennett R, Bombardier C, Goldenberg D, Tugwell P, Campbell S, Abeles M, Clark P (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33(2):160–172PubMedCrossRef

29.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. doi:10.1002/art.1780400928 PubMedCrossRef

30.

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, Healey L, Kaplan S, Liang M, Luthra H, Medsger T, Mitchell D, Neustadt D, Pinals R, Schaller J, Sharp J, Wilder R, Hunder G (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324PubMedCrossRef

31.

LeRoy EC, Black CM, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed

32.

LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573–1576PubMed

33.

Fox R, Robinson C, Curd J, Kozin F, Howell F (1986) Sjögren’s syndrome. Proposed criteria for classification. Arthritis Rheum 29(5):577–585PubMedCrossRef

34.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558PubMedCrossRef

35.

Fries J, Cella D, Rose M, Krishnan E, Bruce B (2009) Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol 36(9):2061–2066. doi:10.3899/jrheum.090358 PubMedCrossRef

36.

Paulus H, Ramos B, Wong W, Ahmed A, Bulpitt K, Park G, Sterz M, Clements P (1999) Equivalence of the acute phase reactants C-reactive protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when used to calculate American College of Rheumatology 20% improvement criteria or the disease activity score in patients with early rheumatoid arthritis. Western consortium of practicing rheumatologists. J Rheumatol 26(11):2324–2331PubMed

37.

Wolfe F (1997) Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 24(8):1477–1485PubMed

38.

Black S, Kushner I, Samols D (2004) C-reactive protein. J Biol Chem 279(47):48487–48490. doi:10.1074/jbc.R400025200 PubMedCrossRef

39.

Kessler S, Dieppe P, Fuchs J, Stürmer T, Günther KP (2000) Assessing the prevalence of hand osteoarthritis in epidemiological studies. The reliability of a radiological hand scale. Ann Rheum Dis 59(4):289–292. doi:10.1136/ard.59.4.289 PubMedCrossRef

40.

van der Heijde D, Klareskog L, Boers M, Landewé R, Codreanu C, Bolosiu HD, Pedersen R, Fatenejad S (2005) Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64(11):1582–1587. doi:10.1136/ard.2004.034371 PubMedCrossRef

41.

Lønning P, Pfister C, Martoni A, Zamagni C (2003) Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol 14:23–32. doi:10.1016/s0093-7754(03)00305-1 CrossRef

42.

Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, Lippe B (2003) Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 88(12):5951–5956. doi:10.1210/jc.2003-031279 PubMedCrossRef

43.

Waterhouse D, Calzone K, Mele C, Brenner D (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189–1197PubMed

44.

Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. Cancer 109(5):832–839. doi:10.1002/cncr.22485 PubMedCrossRef

45.

McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768PubMedCrossRef

46.

van Herk-Sukel M, van de Poll-Franse L, Voogd A, Nieuwenhuijzen G, Coebergh J, Herings R (2010) Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis. Breast Cancer Res Treat 122(3):843–851. doi:10.1007/s10549-009-0724-3 PubMedCrossRef

47.

Baum M (2002) The ATAC (arimidex(TM), tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. Eur J Cancer 38(15):1984–1986PubMedCrossRef

48.

Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556–562. doi:10.1200/jco.2007.11.5451 PubMedCrossRef

Title: The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms
Authors: Victoria K. Shanmugam
James McCloskey
Beth Elston
Sandra J. Allison
Jennifer Eng-Wong
Publication date: 01-01-2012
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1849-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer

Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer

Enhancement of chemotherapeutic efficacy in hypermethylator breast cancer cells through targeted and pharmacologic inhibition of DNMT3b

Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women

Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis

Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer